Optimization of conventional therapy in patients with IBD

Nature Reviews Gastroenterology and Hepatology

Volumn 8, Issue 11, 2011, Pages 646-656

  Taylor, Kirstin M ^a   Irving, Peter M ^a  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; BALSALAZIDE; BECLOMETASONE DIPROPIONATE; BUDESONIDE; CIPROFLOXACIN; CLIPPER; CORTICOSTEROID; DEXAMETHASONE SODIUM PHOSPHATE; IMMUNOMODULATING AGENT; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METRONIDAZOLE; NITROIMIDAZOLE; PLACEBO; PREDNISOLONE; PREDNISOLONE 3 SULFOBENZOATE; PREDOCOL; RIFAXIMIN; UNCLASSIFIED DRUG;

ANUS FISTULA; ARTHRALGIA; BONE MARROW TOXICITY; COMBINATION CHEMOTHERAPY; CROHN DISEASE; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG MEGADOSE; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENTERITIS; ERYTHROCYTE; EVENING DOSAGE; HUMAN; ILEITIS; LIVER TOXICITY; LUMINAL CROHN DISEASE; MONOTHERAPY; MYALGIA; PATIENT COMPLIANCE; PERIANAL CROHN DISEASE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RECURRENT DISEASE; RELAPSE; REMISSION; REVIEW; TREATMENT DURATION; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT;

GASTROENTEROLOGY; GASTROINTESTINAL AGENTS; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATORY BOWEL DISEASES; PRACTICE GUIDELINES AS TOPIC;

EID: 80455122788     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2011.172     Document Type: Review

References (111)

1. Colombel, J. F. et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N. Engl. J. Med. 362, 1383-1395 (2010).
2. Pannacionne, R. et al. Infliximab, azathioprine, or infliximab + azathioprine for treatment of moderate to severe ulcerative colitis: The UC Success Trial. Gastroenterology 140(Suppl. 1), S134 (2011).
3. Gisbert, J. P. & Panes, J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am. J. Gastroenterol. 104, 760-767 (2009).
4. Louis, E. et al. Infliximab discontinuation in Crohn's disease patients in stable remission on combined therapy with immunosuppressors: interim analysis of a prospective cohort study. Gut 57, A66 (2008).
5. Infliximab (review) and adalimumab for the treatment of Crohn's disease. NICE technology appraisal guidance 187. National Institute for Clinical Excellence [online], www.nice.co.uk/guidance/TA187 (2010).
6. Irving, P. M., Gearry, B., Sparrow, M. P. & Gibson, P. R. Review article: appropriate use of corticosteroids in Crohn's disease. Aliment. Pharmacol. Ther. 26, 313-329 (2007).
7. Gearry, R. B. & Irving, P. M. Biologics for inflammatory bowel diseases in the Asia-Pacific: can we afford to use them, can we afford not to? J. Gastroenterol. Hepatol. 24, 1160-1162 (2009).
8. Ford, A. C., Khan, K. J., Talley, N. J. & Moayyedi, P. 5-aminosalicylates prevent relapse of Crohn's disease after surgically induced remission: systematic review and metaanalysis. Am. J. Gastroenterol. 106, 413-420 (2011).
9. Hanauer, S. et al. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group. Am. J. Gastroenterol. 88, 1188-1197 (1993).
10. Kane, S. V. Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment. Pharmacol. Ther. 23, 577-585 (2006).
11. Kane, S. V., Cohen, R. D., Aikens, J. E. & Hanauer, S. B. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am. J. Gastroenterol. 96, 2929-2933 (2001).
12. Cerveny, P. et al. Non-adherence in inflammatory bowel disease: results of factor analysis. Inflamm. Bowel Dis. 13, 1244-1249 (2007).
13. Kane, S., Huso, D., Aikens, J. & Hanauer, S. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am. J. Med. 114, 39-43 (2003).
14. Sandborn, W. J. et al. MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials. Aliment. Pharmacol. Ther. 26, 205-215 (2007).
15. Kamm, M. A. et al. Randomised trial of once-or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut 57, 893-902 (2008).
16. Rubin, D. T. et al. Impact of ulcerative colitis from patients' and physicians' perspectives: results from the UC:NORMAL survey. Inflamm. Bowel Dis. 15, 581-588 (2009).
17. Dignass, A. U. et al. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. Clin. Gastroenterol. Hepatol. 7, 762-769 (2009).
18. Hanauer, S. B. et al. Delayed-release oral mesalamine 4.8mg/day (800mg tablets) compared with 2.4g/day (400mg tablets) for the treatment of mildly to moderately active ulcerative colitis: the ASCEND I trial. Can. J. Gastroenterol. 21, 827-834 (2007).
19. Hanauer, S. B. et al. Delayed-release oral mesalamine at 4.8g/day (800mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am. J. Gastroenterol. 100, 2478-2485 (2005).
20. Sandborn, W. J. et al. Delayed-release oral mesalamine 4.8g/day (800mg tablet) is effective for patients with moderately active ulcerative colitis. Gastroenterology 137, 1934-1943 (2009).
21. Lichtenstein, G. R., Kamm, M. A., Sandborn, W. J., Lynes, A. & Joseph, R. E. MMX mesalazine for the induction of remission in mild-to-moderately active ulcerative colitis:efficacy and tolerability in specific patient subpopulations. Aliment. Pharmacol. Ther. 27, 1094-1102 (2008).
22. Kruis, W. et al. Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis. Aliment. Pharmacol. Ther. 33, 313-322 (2011).
23. Hussain, F. N., Ajjan, R. A. & Riley, S. A. Dose loading with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters. Br. J. Clin. Pharmacol. 49, 323-330 (2000).
24. th American College of Gastroenterology Annual Scientific Meeting San Diego, California: 2009.
25. Safdi, M. et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am. J. Gastroenterol. 92, 1867-1871 (1997).
26. Marteau, P. et al. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double-blind, placebo controlled study. Gut 54, 960-965 (2005).
27. Hanauer, S. et al. Long-term use of mesalazine (Rowasa) suppositories in remission maintenance of ulcerative proctitis. Am. J. Gastroenterol. 95, 1749-1754 (2000).
28. d'Albasio, G. et al. Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study. Am. J. Gastroenterol. 92, 1143-1147 (1997).
29. van Bodegraven, A. A., Boer, R. O., Lourens, J., Tuynman, H. A. & Sindram, J. W. Distribution of mesalazine enemas in active and quiescent ulcerative colitis. Aliment. Pharmacol. Ther. 10, 327-332 (1996).
30. Kamm, M. A. et al. Effect of extended MMX mesalamine therapy for acute, mild-to-moderate ulcerative colitis. Inflamm. Bowel Dis. 15, 1-8 (2009).
31. Orchard, T. R., van der Geest, S. A. & Travis, S. P. Randomised clinical trial: early assessment after 2 weeks of high-dose mesalazine for moderately active ulcerative colitis-new light on a familiar question. Aliment. Pharmacol. Ther. 33, 1028-1035 (2011).
32. Sandborn, W. J. et al. MMX mesalamine (SPD476), a novel, high-strength 5-ASA formulation induces remission of active, mild-to-moderate ulcerative colitis in subjects that are switched from low-dose oral 5-ASA therapy or are 5-ASA naive: an analysis of pooled data from two phase III studies. Digestive Diseases Week Los Angeles, CA: 2006. Poster T1139.
33. Pruitt, R. et al. Balsalazide as alternative therapy to mesalamine dose-escalation for acute, mild to moderate ulcerative colitis. Gastroenterology 122, A299 (2002).
34. Sandborn, W. J., Fazio, V. W., Feagan, B. G. & Hanauer, S. B. AGA technical review on perianal Crohn's disease. Gastroenterology 125, 1508-1530 (2003).
35. Van Assche, G. et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: special situations. J. Crohns Colitis 4, 63-101 (2010).
36. Thia, K. T. et al. Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn's disease: a randomized, doubleblind, placebo-controlled pilot study. Inflamm. Bowel Dis. 15, 17-24 (2009).
37. Blichfeldt, P., Blomhoff, J. P., Myhre, E. & Gjone, E. Metronidazole in Crohn's disease. A double blind cross-over clinical trial. Gastroenterology 13, 123-127 (1978).
38. Steinhart, A. H. et al. Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial. Gastroenterology 123, 33-40 (2002).
39. Brandt, L. J. et al. Metronidazole therapy for perianal Crohn's disease: a follow-up study. Gastroenterology 83, 383-387 (1982).
40. Arnold, G. L., Beaves, M. R., Pryjdun, V. O. & Mook, W. J. Preliminary study of ciprofloxacin in active Crohn's disease. Inflamm. Bowel Dis. 8, 10-15 (2002).
41. Prantera, C. et al. Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin. Aliment. Pharmacol. Ther. 23, 1117-1125 (2006).
42. Rutgeerts, P. et al. Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology 128, 856-861 (2005).
43. Rutgeerts, P. et al. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology 108, 1617-1621 (1995).
44. D'Haens, G. R. et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a randomized, double-blind, placebo-controlled randomized trial. Gastroenterology 135, 1123-1129 (2008).
45. Madden, M. V., McIntyre, A. S. & Nicholls, R. J. Double-blind crossover trial of metronidazole versus placebo in chronic unremitting pouchitis. Dig. Dis. Sci. 39, 1193-1196 (1994).
46. Shen, B. et al. A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis. Inflamm. Bowel Dis. 7, 301-305 (2001).
47. Hurst, R. D., Molinari, M., Chung, T. P., Rubin, M. & Michelassi, F. Prospective study of the incidence, timing and treatment of pouchitis in 104 consecutive patients after restorative proctocolectomy. Arch. Surg. 131, 497-500 (1996).
48. Gionchetti, P. et al. Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis. Aliment. Pharmacol. Ther. 13, 713-718 (1999).
49. Mimura, T. et al. Four-week open-label trial of metronidazole and ciprofloxacin for the treatment of recurrent or refractory pouchitis. Aliment. Pharmacol. Ther. 16, 909-917 (2002).
50. Nygaard, K. et al. Topical metronidazole treatment in pouchitis. Scand. J. Gastroenterol. 29, 462-467 (1994).
51. Isaacs, K. L. et al. Rifaximin for the treatment of active pouchitis: a randomized, double-blind, placebo-controlled pilot study. Inflamm. Bowel Dis. 13, 1250-1255 (2007).
52. Baron, J. H., Connell, A. M., Kanaghinis, T. G., Lennard-Jones, J. E. & Avery Jones, F. Outpatient treatment of ulcerative colitis: comparison between three doses of oral prednisone. Br. Med. J. 2, 1713-1718 (1962).
53. Brignola, C. et al. Steroid treatment in active Crohn's disease: a comparison between two regimens of different duration. Aliment. Pharmacol. Ther. 8, 465-468 (1994).
54. Dignass, A. et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. J. Crohn's Colitis 4, 28-62 (2010).
55. Lichtenstein, G. R., Abreu, M. T., Cohen, R. & Tremaine, W. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 130, 940-987 (2006).
56. Seow, C. H., Benchimol, E. I., Griffiths, A. M., Otley, A. R. & Steinhart, A. H. Budesonide for induction of remission in Crohn's disease. Cochrane Database Systematic Reviews, Issue 3, Art. No.: CD000296. doi:10.1002/14651858. CD000296.pub3 (2008).
57. Sandborn, W. J. et al. Budesonide MMX 9 mg for the induction of remission of mild-to-moderate ulcerative colitis (UC): data from a multicenter, randomized, double-blind placebo-controlled study in North America and India. Gastroenterology 140(Suppl. 1), S124 (2011).
58. Sandborn, W. J. et al. Budesonide MMX 9 mg for induction of remission of mild-to-moderate ulcerative colitis (UC): data from a multicenter, randomized, double-blind placebo-controlled study in Europe, Russia, Israel and Australia. Gastroenterology 140(Suppl. 1), S65 (2011).
59. Campierei, M. et al. Oral beclometasone dipropionate in the treatment of extensive and left-sided active ulcerative colitis: a multicentre randomised study. Aliment. Pharmacol. Ther. 17, 1471-1480 (2003).
60. Manguso, F. & Balzano, A. Meta-analysis: the efficacy of rectal beclomethasone dipropionate vs. 5-aminosalicylic acid in mild to moderate distal ulcerative colitis. Aliment. Pharmacol. Ther. 26, 21-29 (2007).
61. McIntyre, P. B., Marin, F. A., Berghouse, L., English, J. & Lennard-Jones, J. E. Therapeutic benefits from a poorly absorbed prednisolone enema in distal colitis. Gut 26, 822-824 (1985).
62. Rhodes, J. M. et al. Clinical trial: oral prednisolone metasulfobenzoate (Predocol) vs oral prednisolone for active ulcerative colitis. Aliment. Pharmacol. Ther. 27, 228-240 (2008).
63. Bossa, F. et al. Erythrocyte-mediated delivery of dexamethasone in patients with mild-to-moderate ulcerative colitis, refractory to mesalamine: a randomized, controlled study. Am. J. Gastroenterol. 103, 2509-2516 (2008).
64. Prefontaine, E., MacDonald, J. K. & Sutherland, L. R. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database of Systematic Reviews, Art. No.: CD000545. doi:10/1002/14651858. CD000545.pub3 (2010).
65. Ardizzone, S. et al. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 55, 47-53 (2006).
66. Pearson, D. C., May, G. R., Fick, G. H. & Sutherland, L. R. Azathioprine and 6-mercaptopurine in Crohn's disease. A metaanalysis. Ann. Intern. Med. 122, 132-142 (1995).
67. Reinisch, W. et al. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, doubleblind, double-dummy, multicentre trial. Gut 59, 752-759 (2010).
68. Punati, J. et al. Effect of early immunomodulator use in moderate to severe pediatric Crohn disease. Inflamm. Bowel Dis. 14, 949-954 (2008).
69. Gisbert, J. P. et al. Comparative effectiveness of azathioprine in Crohn's disease and ulcerative colitis: a prospective, long-term, follow-up study of 394 patients. Aliment. Pharmacol. Ther. 28, 228-238 (2008).
70. D'Haens, G., Geboes, K. & Rutgeerts, P. Endoscopic and histologic healing of Crohn's (ileo-) colitis with azathioprine. Gastrointest. Endosc. 50, 667-671 (1999).
71. Mantzaris, G. J. et al. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid-dependent Crohn's disease. Inflamm. Bowel Dis. 15, 375-382 (2009).
72. Ramadas, A. V., Gunesh, S., Thomas, G. A., Williams, G. T. & Hawthorne, A. B. Natural history of Crohn's disease in a populationbased cohort from Cardiff (1986-2003): a study of changes in medical treatment and surgical resection rates. Gut 59, 1200-1206 (2010).
73. Prefontaine, E., Sutherland, L. R., Macdonald, J. K. & Cepiou, M. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. Cochrane Database Systematic Reviews, Issue 1. Art. No.: CD000067. doi:10.1002/14651858. CD000067.pub2 (2009).
74. Timmer, A., McDonald, J. W. & Macdonald, J. K. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Systematic Reviews, Issue 1. Art. No.: CD000478. doi:10.1002/14651858. CD000478.pub2 (2007).
75. Gardiner, S. J., Gearry, R. B., Begg, E. J., Zhang, M. & Barclay, M. L. Thiopurine dose in intermediate and normal metabolizers of thiopurine methyltransferase may differ threefold. Clin. Gastroenterol. Hepatol. 6, 654-660 (2008).
76. Hindorf, U. et al. Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease. Gut 55, 1423-1431 (2006).
77. Osterman, M. T., Kundu, R., Lichtenstein, G. R. & Lewis, J. D. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology 130, 1047-1053 (2006).
78. Dubinsky, M. C. et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 118, 705-713 (2000).
79. Hindorf, U., Johansson, M., Eriksson, A., Kvifors, E. & Almer, S. H. Mercaptopurine treatment should be considered in azathioprine intolerant patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 29, 654-661 (2009).
80. Jharap, B. et al. Thiopurine therapy in inflammatory bowel disease patients: analyses of two 8-year intercept cohorts. Inflamm. Bowel Dis. 16, 1541-1549 (2010).
81. Gearry, R. B. et al. Thiopurine methyltransferase and 6-thioguanine nucleotide measurement: early experience of use in clinical practice. Intern. Med. J. 35, 580-585 (2005).
82. Roblin, X. et al. 6-tioguanine monitoring in steroid-dependent patients with inflammatory bowel disease receiving azathioprine. Aliment. Pharmacol. Ther. 21, 829-839 (2005).
83. 8 erythrocytes is a predictive factor of AZA resistance in IBD patients without clinical remission. Gastroenterology 128(Suppl. 2), A12 (2005).
84. Sparrow, M. P., Hande, S. A., Friedman, S., Cao, D. & Hanauer, S. B. Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Clin. Gastroenterol. Hepatol. 5, 209-214 (2007).
85. Ansari, A. et al. Long-term outcome of using allopurinol co-therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease. Aliment. Pharmacol. Ther. 28, 734-741 (2008).
86. Leung, Y., Sparrow, M. P., Schwartz, M. & Hanauer, S. B. Long term efficacy and safety of allopurinol and azathioprine or 6-mercaptopurine in patients with inflammatory bowel disease. J. Crohns Colitis 3, 162-167 (2009).
87. Haines, M. L. et al. Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with adequately controlled inflammatory bowel disease. Inflamm. Bowel Dis. 17, 1301-1307 (2011).
88. Alfadhli, A. A., McDonald, J. W. & Feagan, B. G. Methotrexate for the induction of remission in refractory Crohn's disease. Cochrane Database Systematic Reviews, Issue 1. Art. No.: CD003459. doi:10.1002/14651858. CD003459.pub2 (2005).
89. Patel, V., Macdonald, J. K., McDonald, J. W. & Chande, N. Methotrexate for maintenance of remission in Crohn's disease. Cochrane Database Systematic Reviews, Issue 4. Art. No.: CD006884. doi:10.1002/14651858. CD006884.pub2 (2009).
90. Oren, R. et al. Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicentre trial. Gastroenterology 110, 1416-1421 (1996).
91. Cummings, J. R. et al. Oral methotrexate in ulcerative colitis. Aliment. Pharmacol. Ther. 21, 385-389 (2005).
92. Paoluzi, O. A. et al. Azathioprine or methotrexate in the treatment of patients with steroiddependent or steroid-resistant ulcerative colitis: results of an open-label study on efficacy and tolerability in inducing and maintaining remission. Aliment. Pharmacol. Ther. 16, 1751-1759 (2002).
93. Nathan, D. M., Iser, J. H. & Gibson, P. R. A single center experience of methotrexate in the treatment of Crohn's disease and ulcerative colitis: a case for subcutaneous administration. J. Gastroenterol. Hepatol. 6, 954-958 (2007).
94. Feagan, B. G. et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N. Engl. J. Med. 342, 1627-1632 (2000).
95. Fraser, A. G., Morton, D., McGovern, D., Travis, S. & Jewell, D. P. The efficacy of methotrexate for maintaining remission in inflammatory bowel disease. Aliment. Pharmacol. Ther. 16, 693-697 (2002).
96. Kurnki, D. et al. Bioavailability of oral vs subcutaneous low-dose methotrexate in patients with Crohn's disease. Aliment. Pharmacol. Ther. 18, 57-63 (2003).
97. Teresi, M. E., Crom, W. R., Choi, K. E., Mirro, J. & Evans, W. E. Methotrexate bioavailability after oral and intramuscular administration in children. J. Pediatr. 110, 788-792 (1987).
98. Hoekstra, M. et al. Splitting high-dose oral methotrexate improves bioavailability: a pharmacokinetic study in patients with rheumatoid arthritis. J. Rheumatol. 33, 481-485 (2006).
99. Chong, R. Y., Hanauer, S. B. & Cohen, R. D. Efficacy of parenteral methotrexate in refractory Crohn's disease. Aliment. Pharmacol. Ther. 15, 35-44 (2001).
100. Wahed, M. et al. Efficacy of methotrexate in Crohn's disease and ulcerative colitis patients unresponsive or intolerant to azathioprine/ mercaptopurine. Aliment. Pharmacol. Ther. 30, 614-620 (2009).
101. Stamp, L. et al. The use of low dose methotrexate in rheumatoid arthritis-are we entering a new era of therapeutic drug monitoring and pharmacogenomics? Biomed. Pharmacother. 60, 678-687 (2006).
102. Egan, L. J. et al. A randomized dose-response and pharmacokinetic study of methotrexate for refractory inflammatory Crohn's disease and ulcerative colitis. Aliment. Pharmacol. Ther. 13, 1597-1604 (1999).
103. Weinshilboum, R. M. & Sladek, S. L. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am. J. Human Genet. 32, 651-662 (1980).
104. Ganiere-Monteil, C. et al. Phenotype and genotype for thiopurine methyltransferase activity in the French Caucasian population: impact of age. Eur. J. Clin. Pharmacol. 60, 89-96 (2004).
105. Rossi, A. M., Bianchi, M., Guarnieri, C., Barale, R. & Pacific, G. M. Genotype-phenotype correlation for thiopurine S-methyltransferase in healthy Italian subjects. Eur. J. Clin. Pharmacol. 57, 51-54 (2001).
106. Kamm, M. A. et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology 132, 1-66 (2007).
107. Lichtenstein, G. R. et al. Effect of once-or twicedaily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin. Gastroenterol. Hepatol. 5, 95-102 (2007).
108. Kruis, W. et al. Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial. Gut 58, 223-240 (2009).
109. Kamm, M. A. et al. Randomised trial of once-or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut 57, 893-902 (2008).
110. Hawthorne, A. B. et al. Once daily Asacol in maintenance therapy for ulcerative colitis: a one-year single-blind randomised trial. Gut 60(Suppl. 1), A37-A38 (2011).
111. Gearry, R. B. & Barclay, M. L. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease. J. Gastroenterol. Hepatol. 20, 1149-1157 (2005).